Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Tse

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Mbio|May 6, 2026
Loss of nsp14-exonuclease activity impairs the replication, proofreading, fitness, and pathogenesis of SARS-CoV-2Jordan Anderson-Daniels, Meghan V Diefenbacher, Boyd L Yount, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Nature Communications|October 3, 2022
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concernMatthew R Chang, Luke Tomasovic, Natalia A Kuzmina, et al.
Biorxiv : the Preprint Server for Biology|December 10, 2020
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential MechanismsAna C Puhl, Ethan James Fritch, Thomas R Lane, et al.
Science (New York, N.Y.)|November 13, 2020
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoYixuan J Hou, Shiho Chiba, Peter Halfmann, et al.
Biorxiv : the Preprint Server for Biology|March 16, 2022
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe diseasePanpan Zhou, Ge Song, Wan-Ting He, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
ACS Omega|March 29, 2021
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential MechanismsAna C Puhl, Ethan J Fritch, Thomas R Lane, et al.
Nature Immunology|June 2, 2022
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like virusesWan-Ting He, Rami Musharrafieh, Ge Song, et al.
Cell Host & Microbe|May 15, 2020
Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human AntibodiesEllen Young, Robert H Carnahan, Daniela V Andrade, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Mbio|May 6, 2026
Loss of nsp14-exonuclease activity impairs the replication, proofreading, fitness, and pathogenesis of SARS-CoV-2Jordan Anderson-Daniels, Meghan V Diefenbacher, Boyd L Yount, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Nature Communications|October 3, 2022
IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concernMatthew R Chang, Luke Tomasovic, Natalia A Kuzmina, et al.
Biorxiv : the Preprint Server for Biology|December 10, 2020
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential MechanismsAna C Puhl, Ethan James Fritch, Thomas R Lane, et al.
Science (New York, N.Y.)|November 13, 2020
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoYixuan J Hou, Shiho Chiba, Peter Halfmann, et al.
Biorxiv : the Preprint Server for Biology|March 16, 2022
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe diseasePanpan Zhou, Ge Song, Wan-Ting He, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
ACS Omega|March 29, 2021
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential MechanismsAna C Puhl, Ethan J Fritch, Thomas R Lane, et al.
Nature Immunology|June 2, 2022
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like virusesWan-Ting He, Rami Musharrafieh, Ge Song, et al.
Cell Host & Microbe|May 15, 2020
Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human AntibodiesEllen Young, Robert H Carnahan, Daniela V Andrade, et al.
Pageof 9